Mereo BioPharma (MREO) Change in Accured Expenses (2023 - 2026)
Mereo BioPharma (MREO) posted quarterly Change in Accured Expenses of $229000.0 for Q1 2026, up 116.47% year-over-year from $105786.0 in Q1 2025, and up 110.13% quarter-over-quarter from -$2.3 million in Q4 2025.
Mereo BioPharma (MREO) Change in Accured Expenses (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Change in Accured Expenses for 4 consecutive years, with $229000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 116.47% year-over-year to $229000.0; the TTM figure through Mar 2026 stood at -$775000.0 (down 317.09% YoY), while the FY2025 annual figure was -$2.4 million, down 100.84% from the prior year.
- Change in Accured Expenses rose to $229000.0 in Q1 2026 per MREO's latest filing, from -$2.3 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $4.2 million in Q2 2023 and bottomed at -$3.1 million in Q1 2023.
- Historically, Change in Accured Expenses has averaged -$312846.2 across 4 years, with a median of -$706000.0 in 2024.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses sank 442.47% — and 2026, when it soared 116.47%.
- Mereo BioPharma's Change in Accured Expenses stood at -$1.7 million in 2023, then jumped by 58.79% to -$706000.0 in 2024, then tumbled by 220.25% to -$2.3 million in 2025, then surged by 110.13% to $229000.0 in 2026.
- Business Quant data shows MREO's Change in Accured Expenses at $229000.0 in Q1 2026, -$2.3 million in Q4 2025, and -$673000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | 577,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 577,000.00 |
| Jun 30, 2026 | 577,000.00 |
| Mar 31, 2026 | 229,000.00 |
| Mar 31, 2026 | 229,000.00 |
| Dec 31, 2025 | -2.26 Mn |
| Dec 31, 2025 | -2.26 Mn |
| Sep 30, 2025 | -673,000.00 |
| Sep 30, 2025 | -673,000.00 |
| Jun 30, 2025 | 1.93 Mn |
| Jun 30, 2025 | 1.93 Mn |
| Mar 31, 2025 | -1.39 Mn |
| Mar 31, 2025 | -1.39 Mn |
| Dec 31, 2024 | -706,000.00 |
| Dec 31, 2024 | -706,000.00 |
| Sep 30, 2024 | -792,000.00 |
| Sep 30, 2024 | -792,000.00 |
| Jun 30, 2024 | 3.25 Mn |
| Jun 30, 2024 | 3.25 Mn |
| Mar 31, 2024 | -2.94 Mn |
| Mar 31, 2024 | -2.94 Mn |